Why Is HEMAB THERAPEUTICS H (COAG) Stock Down Today?

Hemab Therapeutics (COAG) shares fell 9.44% to $38.77, driven by a third-quarter earnings miss and the initiation of a pivotal Phase III clinical trial. The stock declined despite the company announcing that its cash runway extends to 2029.

What Happened

Hemab Therapeutics reported third-quarter 2026 financial results, disclosing a GAAP EPS of -$0.58. This figure missed analyst estimates by $0.06. The company filed a Form 8-K with the SEC on November 10, 2026, to disclose these results and accompanying financial statements.

Simultaneously, the company initiated SOLARA, a pivotal Phase III trial for sutacimig in Glanzmann thrombasthenia. This is the company’s first Phase III trial, designed to evaluate once-weekly subcutaneous sutacimig in approximately 75 participants. The study features a single-arm design with a 24-week run-in period followed by 48 weeks of treatment. During the earnings call, President and CEO Benny Sorensen noted that the company’s cash runway reaches 2029 as enrollment for the SOLARA trial begins.

What The Data Shows

The stock’s market capitalization stands at $2.3 billion. The company remains unprofitable, with a trailing twelve-month EPS of -$10.06. The share price currently trades within a 52-week range of $23.00 to $55.42. On November 10, 2026, the stock printed three fresh 52-week highs and 23 fresh 52-week lows.

What To Watch

Investors will monitor the progress of the SOLARA Phase III trial, which is the company’s first of its kind. The upcoming earnings date has not been specified in the provided data, so coverage breadth and clinical trial milestones remain the primary focus.